This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Five years have elapsed since the first edition of this book, and a lot has happened to pharmacoepidemiology in that time. (The reprinted preface to the first edition is mysteriously dated three years too early.) There are now a large International Society of Pharmacoepidemiology and a spate of journals devoted to the art and science of the field. Pharmacoepidemiologic data, coupled with pharmacoeconomic data and quality-of-life studies, play an increasingly important role in drug approval, drug withdrawal, and decisions about drug pricing and reimbursement.
To take account of these and other changes, editor Brian Strom has added 17 new chapters and dropped two old ones. The result is a more complete and more useful book than its predecessor, which was already a significant contribution to the education of members of many disciplines and professions.
As before, there is considerable attention given to various databases, and their strengths and weaknesses are
Lasagna L. Pharmacoepidemiology. JAMA. 1995;273(12):970-971. doi:10.1001/jama.1995.03520360084048